The moms and dad business of MoviePass might quickly no longer have its shares trading on the Nasdaq market.

The Nasdaq cautioned Helios and Matheson on Wednesday that it prepares to suspend trading in the business’s shares on December 28 and will relocate to have them delisted, Helios and Matheson divulged Friday in a file submitted with the Securities and Exchange Commission The business prepares to postpone and possibly avoid the delisting by appealing the exchange’s choice.

However the business’s possibilities of winning an appeal might be slim. The Nasdaq currently chose that it will not offer Helios and Matheson a 180- day extension to get its stock back above $1 a share, the requirement which it has actually stopped working to fulfill considering that May of this year.

Helios and Matheson “got a composed notification from [Nasdaq’s] personnel that the business has actually not gained back compliance with [Nasdaq’s listing standards] and is not qualified for a 2nd 180- day duration since the personnel identified that it does not appear that it is possible for the business to treat the shortage,” the business stated in its regulative filing.

The MoviePass owner suggested in the file that it still thinks it can increase its stock above $1 a share and restore compliance. It stated it would appeal the choice and request a hold-up so that it can reverse split its stock a 2nd time. It likewise stated it would “continue thinking about all readily available choices to deal with the business’s noncompliance” with the listing requirement.

Read this: MoviePass’ moms and dad business simply purchased itself more time to live, however it’s still in impending risk of being began the stock market

Helios and Matheson’s stock has actually been stuck listed below $1 a share

Nasdaq’s guidelines need it to put the delisting procedure on hold when a business appeals the delisting choice. Appeals are normally held within 45 days of their filing, according to the file. Need To Helios and Matheson not in fact appeal the delisting choice or lose its appeal, its shares would likely wind up on the non-prescription markets where they would be harder to trade and would likely decrease even further than they currently have. The business’s stock has actually lost more than 99% of its worth this year as its burned through more than $300 million in money and sold billions of shares to remain in organisation

In June, after Helios and Matheson’s stock had actually been listed below $1 a share for more than a month, the Nasdaq sent out the business a letter cautioning that it was not in compliance with the marketplace’s listing requirements. Nasdaq offered Helios and Matheson 180 days to increase its share cost and resolve the issue.

After getting approval from investors, it reverse split its stock by a 250- to-1 ratio in July, momentarily improving its stock cost above $20 a share. However the shares rapidly dropped listed below $1 a share once again as the business provided and offered enormous amounts of brand-new shares to money its continuous losses

Helios and Matheson proposed reverse splitting its stock once again this fall, however it wound up deserting the effort in the face of prevalent financier opposition

The Nasdaq mentioned that history in describing why it would not offer Helios and Matheson a 2nd 180- day duration to return in compliance with its listing requirements, according to the regulative file.